Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

– Annamycin continues to demonstrate no evidence of cardiotoxicity to date, now in a total of 62 subjects across three of the Company’s Annamycin clinical trials – Next generation anthracycline, Annamycin, has demonstrated both safety and promising early activity across multiple clinical studies with potential to be an effective treatment across multiple oncology indications HOUSTON, Sept. 18, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced it has received a new independent assessment for the absence of cardiotoxicity in subjects treated with Annamycin. Data from the following subjects were made available to an expert in chemotherapy who is affiliated with a leading cancer research institute in assessing cardiotoxicity. After review of this data, the independent expert concluded that there was no evidence of cardiotoxicity:

The release as fetched from its publisher. moleculin.com ↗